{'52WeekChange': 1.6366994,
 'SandP52WeekChange': 0.0644362,
 'address1': '430 East 29th Street',
 'address2': 'Suite 900',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 21.95,
 'askSize': 800,
 'averageDailyVolume10Day': 653012,
 'averageVolume': 879066,
 'averageVolume10days': 653012,
 'beta': 1.928851,
 'beta3Year': None,
 'bid': 21.4,
 'bidSize': 1000,
 'bookValue': 6.502,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 21.61,
 'dayLow': 20.6231,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.009,
 'enterpriseToRevenue': 871.155,
 'enterpriseValue': 996681024,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '646 440 9334',
 'fiftyDayAverage': 23.535715,
 'fiftyTwoWeekHigh': 43.56,
 'fiftyTwoWeekLow': 6.75,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 58339574,
 'forwardEps': -2.65,
 'forwardPE': -8.079245,
 'fromCurrency': None,
 'fullTimeEmployees': 330,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.06066,
 'heldPercentInstitutions': 0.69587,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/intracellulartherapies.com',
 'longBusinessSummary': 'Intra-Cellular Therapies, Inc., a biopharmaceutical '
                        'company, develops novel drugs for the treatment of '
                        'neuropsychiatric and neurologic diseases, and other '
                        'disorders of the central nervous system (CNS) in the '
                        'United States. The company is developing its lead '
                        'drug candidate, CAPLYTA for the treatment of '
                        'schizophrenia, bipolar disorder, behavioral '
                        'disturbances associated with dementia, autism, and '
                        'other CNS diseases. It is also developing ITI-002 '
                        'that inhibits the enzyme phosphodiesterase type 1; '
                        "ITI-214 for Parkinson's disease; and ITI-333, for "
                        'substance use disorders, pain, and psychiatric '
                        'comorbidities, including depression and anxiety. '
                        'Intra-Cellular Therapies, Inc. is headquartered in '
                        'New York, New York.',
 'longName': 'Intra-Cellular Therapies, Inc.',
 'market': 'us_market',
 'marketCap': 1422705152,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_9425271',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -160297024,
 'nextFiscalYearEnd': 1640908800,
 'open': 21.09,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '646 440 9333',
 'previousClose': 21.36,
 'priceHint': 2,
 'priceToBook': 3.292833,
 'priceToSalesTrailing12Months': 1243.5234,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 21.61,
 'regularMarketDayLow': 20.6231,
 'regularMarketOpen': 21.09,
 'regularMarketPreviousClose': 21.36,
 'regularMarketPrice': 21.09,
 'regularMarketVolume': 669330,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 66450500,
 'sharesPercentSharesOut': 0.0799,
 'sharesShort': 5311551,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 4918170,
 'shortName': 'Intra-Cellular Therapies Inc.',
 'shortPercentOfFloat': 0.0919,
 'shortRatio': 5.14,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'ITCI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.779,
 'twoHundredDayAverage': 21.044065,
 'volume': 669330,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.intracellulartherapies.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10016'}